Hit Tumors* Hard With TheraSphere

Interventional Oncology / Cancer Therapies & Ablation / TheraSphere
TheraSphere receives FDA Approval.

TheraSphere receives FDA Approval!

After 20 years as a humanitarian exemption device (HDE), the FDA grants TheraSphere pre-market approval, making TheraSphere the only Y-90 therapy indicated for HCC. The FDA has also granted Breakthrough Device designation for TheraSphere treatment for patients with glioblastoma.*

*TheraSphere has not been approved for treatment of patients with glioblastoma

Become An Authorized User ›
The TARGET Study.

The TARGET Study

The TARGET Study is a global, real-world data set across 8 countries demonstrating the reproducibility of treatment with TheraSphere Y-90 glass microspheres, confirmed by Simplicit90Y™ Personalized Dosimetry Software.

Learn More


Proven. Personalized. Precise.

Strike first with three distinct advantages. We have a proven therapy to fight primary liver cancer.1 We deploy a custom personalized dose to extend life, to improve life. We act with expert precision.

patient image.

Your patients are fighting for more than their survival. They’re fighting for their quality of life. TheraSphere is uniquely able to help you strike first on both fronts.

glass beads image.

Glass Matters With Y-90

Give your patients a fighting chance with TheraSphere Y-90 Glass Microspheres. These precision-manufactured glass microspheres are the most powerful radiation therapy on the market.

1. Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y-90 as primary treatment for HCC informed by a 1,000-patient 15-year experience. Hepatology. 2017 Dec 1. 

*Refers to HCC or associated tumors